FY23 Research

FY23

Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial (2022)

Kent Hutchison, PhD
Institute of Cognitive Science Affiliated Faculty & Professor, University of Colorado Boulder

Traumatic brain injury (TBI) represents a major public health burden due to chronic neuropsychiatric sequelae (emotional, physical and cognitive) that negatively affect vocational activities, interpersonal relationships and independent living. Responses of these chronic symptoms to any particular treatment are both variable […]

Learn More »
FY23

Potential Health Effects of Heavy Metals in Cannabis Flower, Concentrates, Vape Devices, and Vape Emissions (2022)

Mike Van Dyke, PhD
Associate Professor, Center for Health, Work, and Environment, Colorado School of Public Health, University of Colorado Anschutz Medical Campus

Inhalation exposure to heavy metals such as lead, cadmium, arsenic, nickel, mercury, and manganese can increase the risk for cancer as well as neurological, renal, cardiovascular, and hepatic outcomes. Smoking or vaping cannabis […]

Learn More »
FY23

Examining the adaptive roles of plant defensive chemistry on pest resistance in Cannabis sativa (2022)

Punya Nachappa, PhD
Associate Professor, Entomology, Department of Agricultural Biology, Colorado State University

Understanding how plants respond to insect herbivores can provide new insights into plant-insect chemical communication and coevolution and facilitate new approaches to crop protection. Cannabis is known for the presence of cannabinoids, which include Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and more than 100 […]

Learn More »
FY23

Isolation and Pharmacological Evaluation of Phytocannabinoids for Alzheimer’s Disease (2022)

Duncan Mackie, PhD,
Director of Pharmacology & Experimental Therapeutics, MedPharm Holdings

Cinnamon Bidwell, PhD,
Institute of Cognitive Science Faculty, Assistant Professor, University of Colorado Boulder

Our research group has a longstanding interest in the activity of cannabinoids for the treatment of inflammatory neurological diseases such as Alzheimer’s disease. The purpose of this proposal is to further develop […]

Learn More »
FY23

Preventative and treatment effects of broad-spectrum cannabidiol (CBD) in a rat model of comorbid autism and epilepsy: A mechanistic study (2022)

Christopher Lowry, PhD
Associate Professor, Integrative Physiology, University of Colorado Boulder

Over 50% of children with autism spectrum disorder (ASD) show sub-clinical epileptic spikes by adolescence and 5-40% develop chronic epilepsy. Similarly, approximately 30% of children with epilepsy are also diagnosed with ASD. As a likely etiology, the role of inflammation in epilepsy is under intense […]

Learn More »